Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Brand, Same MS Drug: Novartis Launches Extavia In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis lays foundation for potential MS platform with European launch of its own branded version of Bayer-Schering’s Betaferon (interferon beta-1b).

You may also be interested in...

Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help

Tysabri’s REMS could prove to be a model for drugs with serious safety signals.

Biosimilars Create Class-wide Competition, German Experience Finds

Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis

Omnitrope’s Improved Delivery System Already Getting Formulary Traction

Sandoz sued FDA in its effort to win approval of Omnitrope (somatropin [rDNA origin]). Now the company is using more mundane regulatory procedures as it works to expand sales of its follow-on human growth hormone

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts